Risk of gastrointestinal bleeding with aspirin and platelet antiaggregants;Riesgo de hemorragia digestiva con aspirina y antiagregantes plaquetarios

Gastroenterologia y Hepatologia

Volumn 32, Issue 1, 2009, Pages 36-43

  Nardulli, Gianfranco ^a   Lanas, Ángel ^b  

^a HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^b UNIVERSITY OF ZARAGOZA   (Spain)

Author keywords

Aspirin; Gastrointestinal bleeding; Platelet antiaggregants

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2 INHIBITOR; ESOMEPRAZOLE; LANSOPRAZOLE; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROSTAGLANDIN E2; PROTON PUMP INHIBITOR; TICLOPIDINE;

AGE DISTRIBUTION; AGING; ARTICLE; CLINICAL TRIAL; DIGESTIVE SYSTEM PERFORATION; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HELICOBACTER INFECTION; HUMAN; INTRACARDIAC THROMBOSIS; LOW DRUG DOSE; PEPTIC ULCER; RISK FACTOR; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS PREVENTION;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICOAGULANTS; ASPIRIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; GASTROINTESTINAL HEMORRHAGE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HISTAMINE H2 ANTAGONISTS; HUMANS; MIDDLE AGED; MISOPROSTOL; PEPTIC ULCER HEMORRHAGE; PLATELET AGGREGATION INHIBITORS; PROTON PUMP INHIBITORS; RISK FACTORS; THROMBOXANES; TICLOPIDINE;

EID: 63349100445     PISSN: 02105705     EISSN: 15789519     Source Type: Journal    
DOI: 10.1016/j.gastrohep.2008.02.001     Document Type: Article

References (50)

1. Zundorf U. 100 years of aspirin: the future has just begun (1997), Bayer AG, Leverkusen
2. Esmatjes E., Castell C., Franch J., Puigoriol E., and Hernáez R. Consumo de ácido acetilsalicílico en pacientes con diabetes mellitus. Med Clin (Barc) 122 (2004) 96-98
3. Campbell C.L., Smyth S., Montalescot G., et al. Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA 297 (2007) 2018-2024
4. Rivkin A. Admissions to a medical intensive care unit related to adverse drug reactions. Am J Health Syst Pharm 64 (2007) 1840-1843
5. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 308 (1994) 81-106
6. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324 (2002) 71-86
7. Lee M., Cryer B., and Feldman M. Dose effects of aspirin on gastric prostaglandins and stomach mucosal injury. Ann Intern Med 120 (1994) 184-189
8. Yeomans N.D., Lanas A.I., Talley N.J., Thomson A.B., Daneshjoo R., Eriksson B., et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther 22 (2005) 795-801
9. Chowdhury A., Ganguly G., Chowdhury D., et al. Gastro-duodenal mucosal changes associated with low-dose aspirin therapy: a prospective, endoscopic study. Indian J Gastroenterol 20 (2001) 227-229
10. Laine L., Maller E.S., Yu C., Quan H., and Simon T. Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a doubleblind trial. Gastroenterology 127 (2004) 395-402
11. Pirmohamed M., James S., Meakin S., et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 329 (2004) 15-19
12. Weil J., Colin-Jones D., Langman M., et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 310 (1995) 827-830
13. Derry S., and Loke Y.K. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ 321 (2000) 1183-1187
14. García Rodríguez L.A., Hernández-Díaz S., and De Abajo F.J. Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. Br J Clin Pharmacol 52 (2001) 563-571
15. Weil J., Colin-Jones D., Langman M., et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 310 (1995) 827-830
16. Lanas A., Bajador E., Serrano P., et al. Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med 343 (2000) 834-839
17. Ibañez L., Vidal X., Vendrell L., et al. Upper gastrointestinal bleeding associated with antiplatelet drugs. Aliment Pharmacol Ther 23 (2006) 235-242
18. De Abajo F.J., and García Rodríguez L.A. Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations. BMC Clin Pharmacol 1 (2001) 1
19. Kelly J.P., Kaufman D.W., Jurgelon J.M., et al. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 348 (1996) 1413-1416
20. Lanas A., Pérez-Aisa M.A., Feu F., et al. A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal anti-inflammatory drug use. Am J Gastroenterol 100 (2005) 1685-1693
21. McQuaid K.R., and Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med 119 (2006) 624-638
22. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 120 (2001) 594-606
23. Lanas A., Bajador E., Serrano P., et al. Nitrovasodilators, low-dose aspirin, other nonsteroidal anti-inflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med 343 (2000) 834-839
24. Serrano P., Lanas A., Arroyo M.T., and Ferreira I.J. Risk of upper gastrointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular diseases. Aliment Pharmacol Ther 16 (2002) 1945-1953
25. Chan F.K., Chung S.C., Suen B.Y., et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 344 (2001) 967-973
26. Lanas A., Fuentes J., Benito R., et al. Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin. Aliment Pharmacol Ther 16 (2002) 779-786
27. Patrono C., García Rodríguez L.A., Landolfi R., and Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 353 (2005) 2373-2383
28. The Medical Research Council's General Practice Research Framework. Thrombosis Prevention Trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 351 (1988) 233-241
29. Johnson W.C., Williford W.O., and Department of Veterans Affairs Cooperative Study #362. Benefits, morbidity, and mortality associated with long-term administration of oral anticoagulant therapy to patients with peripheral arterial bypass procedures: a prospective randomized study. J Vasc Surg 35 (2002) 413-421
30. Nielsen G.L., Sorensen H.T., Mellemkjoer L., et al. Risk of hospitalization resulting from upper gastrointestinal bleeding among patients taking corticosteroids: a register-based cohort study. Am J Med 111 (2001) 541-545
31. Lanas A., García-Rodríguez L.A., Arroyo M.T., Gomollón F., Feu F., González-Pérez A., et al., Asociación Española de Gastroenterología. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 55 (2006) 1731-1738
32. Sorensen H.T., Mellemkjaer L., Blot W.J., et al. Risk of upper gastrointestinal bleeding associated with use of lowdose aspirin. Am J Gastroenterol 95 (2000) 2218-2224
33. Lanas A., García-Rodríguez L.A., Arroyo M.A., Gomollón F., Zapata E., Bujanda L., et al. Coxibs, NSAIDs, aspirin, PPIs and the risks of upper GI bleeding in common clinical practice. Gastroenterology 128 (2005) 629
34. Silverstein F.E., Faich G., Goldstein J.L., Simon L.S., Pincus T., Whelton A., et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284 (2000) 1247-1255
35. Schnitzer T.J., Burmester G.R., Mysler E., Hochberg M.C., Doherty M., Ehrsam E., et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 364 (2004) 665-674
36. Singh G., Fort J.G., Goldstein J.L., Levy R.A., Hanrahan P.S., Bello A.E., et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. Am J Med 119 (2006) 255-266
37. Sopena F., and Lanas A. How to advise aspirin use in patients who need NSAIDs. Curr Pharm Des 13 (2007) 2248-2260
38. Huang J.Q., Sridhar L., and Hunt R.H. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 359 (2002) 14-22
39. Papatheodoridis G.V., Sougioultzis S., and Archimandritis A.J. Effects of Helicobacter pylori and nonsteroidal anti-inflammatory drugs on peptic ulcer disease: a systematic review. Clin Gastroenterol Hepatol 4 (2006) 130-142
40. Bombardier C., Laine L., Reicin A., Shapiro D., Burgos-Vargas R., Davis B., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343 (2000) 1520-1528
41. CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348 (1996) 1329-1339
42. Lanas A., García-Rodríguez L.A., Arroyo M.T., et al., Investigators of the Asociación Española de Gastroenterología (AEG). Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am J Gastroenterol 102 (2007) 507-515
43. Rostom A., Dube C., Wells G., Tugwell P., Welch V., Jolicoeur E., et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev 4 CD002296 (2004) 1-11
44. Lai K.C., Lam S.K., Chu K.M., et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 346 (2002) 2033-2038
45. Chan F.K., Ching J.Y., Hung L.C., et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 352 (2005) 238-244
46. Lai K.C., Chu K.M., Hui W.M., et al. Esomeprazole with aspirin versus clopidogrel for prevention of recurrent gastrointestinal ulcer complications. Clin Gastroenterol Hepatol 4 (2006) 860-865
47. Lanas A., Fuentes J., Benito R., Serrano P., Bajador E., and Sainz R. Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin. Aliment Pharmacol Ther 16 (2002) 779-786
48. Chan F., Ching J., Suen B., Wong V., Hung L., Hui A., et al. Eradication of H. pylori for the prevention of recurrent ulcer bleeding in high-risk aspirin users: a 4-year prospective cohort study. Gastroenterology 128 (2005) 835
49. Lanas A., and Ferrández A. Inappropriate prevention of NSAID-induced gastrointestinal events among long-term users in the elderly. Drugs Aging 24 (2007) 121-131
50. García Rodríguez L.A., Hernández-Díaz S., and De Abajo F.J. Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. Br J Clin Pharmacol 52 (2001) 563-571